Rare diseases represent a special challenge for the translation of new therapies into patient care. Duchenne muscular dystrophy (DMD) is a rare childhood-onset muscular dystrophy; curative treatment is not yet available. However, new therapies are emerging to fight this devastating disease. In order to establish an infrastructure to improve data harmonisation, knowledge on the disease, public awareness, industrial interest and trial readiness, patient registries are an indispensable resource. This article provides a short overview on their importance and benefits towards improving diagnosis and care.
Duchenne muscular dystrophy (DMD) is the most common X-chromosomal inherited muscle disease in children. Nevertheless, having an estimated incidence of 1:5,000 male newborns, it is classified as a rare disorder. 1 DMD results in progressive muscle weakness and severe disability, cardiopulmonary comorbidity and reduced life expectancy. Affected boys are limited in their independency, private and public roles, education and professional lives. No curative treatment is yet available, but symptomatic and interdisciplinary medical care represent the most important components for improving the outcome and quality of life of these patients. 2, 3 New curative therapies are under development, 4 but rare disorders present a peculiar challenge to the translational process from bench to bedside.
Prerequisites for Translation
Translation from bench to bedside -the invention of new therapiescovers the progress from preclinical research to human application and clinical trials, to market authorisation, and to implementation into Kirschner et al. 6 more than 3 years to enrol 150 ambulant DMD patients in an investigator-driven, multicentre trial in Germany. For industrysponsored trials, a trial recruitment phase lasting more than 1 year is absolutely infeasible for economic reasons. So, a patient registry facilitating quick and efficient patient identification for enrolment may be a mandatory prerequisite for enabling clinical trials in DMD.
How Can Patient Registries Support the Translational Process in Duchenne Muscular Dystrophy?
Within the international network of excellence TREAT-NMD (funded by the EC 2007-2011), the implementation of internationally harmonised patient registries for DMD (and additional hereditary neuromuscular disorders) was highly supported. 7, 8 Meanwhile, extensive international cooperation and networking resulted in more than 50 national DMD registries, all adapted to a harmonised data content and providing pseudonomised data for a global database. Only a few studies had been published in this field before patient registries were established, with retrospective data acquisition of homogenous patient cohorts being difficult. 14, 15 Patient registries help define patient cohorts according to specified criteria and address patients directly, so retrospective or even prospective health economics evaluations, health services research and patients' quality-of-life evaluations can be achieved more easily. 16, 17 These advancements in DMD care, accomplished via the patient registries, can represent a model for other rare disorders and may contribute to a more comprehensive understanding of health care delivery matters in rare disorders in general. 
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